Daxor Corporation

254 articles with Daxor Corporation

• Daxor Corporation to Present at the 13th Annual LD Micro Main Event 2020

  12/9/2020

  Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces that Michael Feldschuh, Daxor’s President and Chief Executive Officer, will present at the virtual 2020 LD MicroCap Main Event on December 14, 2020 at 10:40 AM ET in Track One: Top Dollar.

• THIRD HOSPITAL JOINS MULTICENTER COVID-19 BVA-100® BLOOD TEST STUDY

  11/19/2020

  Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that Wake Forest Baptist Health will participate in an ongoing trial to treat patients hospitalized with COVID-19 utilizing Daxor's BVA-100 (Blood Volume Analyzer, "BVA") technology.

• Oregon Health & Science University Joins Multicenter Covid-19 BVA-100® Study

  10/29/2020

  COVID-19 Investigation Continues at OHSU to Study Hospitalized Patients Utilizing Daxor’s Blood Volume Analysis Technology

• Daxor to Present at the 2020 MicroCap Rodeo Best Ideas Bowl

  10/12/2020

  Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces that Michael Feldschuh, Daxor’s President and Chief Executive Officer, will present at the virtual 2020 MicroCap Rodeo Best Ideas Bowl on Tuesday, October 13th at 3:00 PM ET. Mr. Feldschuh will provide a company overview and discuss key highlights including new researc

• New Research Shows Daxor’s BVA-100® Blood Test Provides Unique Benefit in Detecting Anemia and Heart Failure Risk, Presented at the Heart Failure Society of America Meeting 2020

  10/6/2020

  Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces new data presented during the Heart Failure Society of America’s Annual Scientific Meeting focused on the use of Daxor’s BVA-100® blood test for uniquely measuring anemia.

• New Research Demonstrates Daxor BVA-100® Blood Test Provides “Extremely Cost-Effective” Improvement in Patient Life Span at the Heart Failure Society of America Annual Scientific Meeting 2020

  10/5/2020

  Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces compelling new data demonstrating further beneficial use of Daxor’s blood volume analysis technology presented during the Heart Failure Society of America’s Virtual Annual Scientific Meeting 2020.

• New Data Released from the Mayo Clinic Utilizing Daxor’s BVA-100® Test Highlights Value of Daxor’s Diagnostic at the Heart Failure Society of America Virtual Annual Scientific Meeting 2020

  10/2/2020

  Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces new data from the Mayo Clinic showing that Daxor’s Blood Volume diagnostic test utilizing its BVA-100 device is clinically superior to the common proxy marker of weight loss to measure progress in heart failure (HF) treatment.

• Daxor Corporation to Exhibit and Showcase Compelling New Data at the Heart Failure Society of America Virtual Annual Scientific Meeting 2020 on the Value of BVA-100®

  9/28/2020

  Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces the Company will be exhibiting and showcasing new data at the Heart Failure Society of America’s (HFSA) Virtual Annual Scientific Meeting 2020 taking place from September 30th - October 6th, 2020. The Company will host a booth and will be available online throughout the e

• Daxor to Present at the Inaugural Sepsis Alliance Summit

  9/15/2020

  Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces the Company will be participating in the inaugural Sepsis Alliance Summit.

• Daxor to Present at H.C. Wainwright 22nd Annual Global Investment Conference

  9/10/2020

  Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces that Michael Feldschuh, Daxor’s President & Chief Executive Officer, will present at the virtual H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020, at 2:00 PM ET. The Company will present virtually and provide updates about re

• Daxor Corporation to Present at the LD 500 Virtual Investor Conference

  8/31/2020

  Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces that it will be presenting at the LD 500 Virtual Investor Conference scheduled to take place from September 1-4, 2020.

• Daxor Corporation reports a 29.6 Percent Rise in Sales Revenue for Six Months in Filing of Form N-CSR for June 30, 2020

  8/24/2020

  Daxor Corporation (NYSE MKT: DXR) , an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, filed a Form N-CSR disclosing its schedule of portfolio holdings as of June 30, 2020. Daxor reported an increase in revenue of 29.6% in the Company’s diagnostic division representing strong strides in the commercialization of its BVA-100 Blood Volume Analyzer. Further sales are expected

• DAXOR ANNOUNCES COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT WITH THE UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES

  8/4/2020

  Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that it has entered into a Cooperative Research and Development Agreement (“CRADA”) with The Uniformed Services University of the Health Sciences (“USU”), an institution of higher learning within the United States Department of Defense (DoD), and The Henry M. Jackson Foundat

• Daxor Corporation Announces Pricing of $7.0 Million Registered Direct Offering

  7/20/2020

  Daxor Corporation (NYSE American: DXR)  (“Daxor” or the “Company”), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that it has entered into definitive agreements with several institutional investors for the purchase in a registered direct offering of 125,000 shares of its common stock from the Company, and 225,000 shares of its common stock from the Estat

• DAXOR ANNOUNCES PROSPECTIVE RANDOMIZED CONTROL TRIAL AT DUKE UNIVERSITY MEDICAL CENTER TO GUIDE VOLUME TREATMENT IN HEART FAILURE PATIENTS

  7/16/2020

  Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced the initiation of a prospective randomized control trial (RTC) utilizing Daxor’s BVA-100 (Blood Volume Analyzer, “BVA”) technology to guide volume treatment in heart failure patients.

• Daxor Announces Initiation of First-of-Its-Kind Multicenter BVA-100® Study in Hospitalized Patients With COVID-19

  7/15/2020

  Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced the initiation of a multicenter prospective study utilizing Daxor’s BVA-100 (Blood Volume Analyzer, “BVA”) technology in hospitalized COVID-19 patients. NYU Langone Health

• DAXOR ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH AMERICAN MEDICAL DEPOT GOVERNMENT DISTRIBUTOR

  7/8/2020

  Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, has signed a new distribution agreement with American Medical Depot “AMD,” one of the nation’s largest and diversified government healthcare distributors. As part of the agreement, the two parties are set to provide Daxor’s BVA-100 diagnostic blood test (Blood Volume Analysis) “BVA,” to gov

• Daxor Corporation Announces Appointment of Henry D. Cremisi, MD, FACP and Joy Goudie, Esq. to the Company’s Board of Directors

  6/30/2020

  Daxor Corporation, an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, announced the appointments of Dr. Henry D. Cremisi and Joy Goudie, Esq. to the Company's Board of Directors, effective June 29, 2020.

• Daxor Corporation, CEO Michael Feldschuh to Participate in Maxim Group’s COVID-19 Virtual Conference on May 27, 2020

  5/26/2020

  Daxor Corporation, an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, announced that its CEO, Michael Feldschuh, will be a panelist in Maxim Group and M-Vest’s COVID-19 Virtual Series on May 27, 2020.

• Daxor’s BVA-100® Published in Novel Study in American Heart Association Journal - Circulation

  5/22/2020

  Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that blood volume outcome data has been published in the scientific journal, Circulation , utilizing Daxor’s BVA-100 blood volume measurement device to determine the primary endpoint of the study, Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects, at Yale U